V.F.Snegirev Archives of Obstetrics and GynecologyV.F.Snegirev Archives of Obstetrics and GynecologyАрхив акушерства и гинекологии им. В.Ф. Снегирева2313-87262687-1386Eco-Vector3526510.17816/aog35265Original study articlesОригинальные исследованияOriginal study articlesResearch ArticleAngiogenic growth factors in the pathogenesis of pre-eclampsiaАнгиогенные факторы роста в патогенезе преэклампсииMurashkoA. VМурашкоАндрей Владимирович

д-р мед. наук, проф., зав. отделением патологии беременности № 1

murashkoa@mail.ruFaizullinA. LФайзуллинА. ЛMurashkoL. EМурашкоЛ. ЕI.M. Sechenov First Moscow State Medical UniversityГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава РоссииV.I. Kulakov Center of Obstetrics, Gynecology, and PerinatologyФГБУ «Научный центр акушерства, гинекологии и перинатологии им. акад. В.И. Кулакова» Минздрава России1509201523VOL 2, NO3 (2015)ТОМ 2, №3 (2015)4721072020Copyright ©; 2015, Eco-VectorCopyright ©; 2015, ООО "Эко-Вектор"2015Eco-VectorООО "Эко-Вектор"https://archivog.com/2313-8726/article/view/35265

The pathogenetic mechanisms of pre-eclampsia are reviewed, modern risk factors are described, and probable consequences for the mother during the postpartum period and for the fetus in postnatal life are discussed.

Представлен обзор патогенетических механизмов развития преэклампсии, описаны современные факторы риска, освещены возможные последствия для матери в послеродовом периоде и плода в дальнейшей постнатальной жизни.

pre-eclampsiaangiogenic growth factorsпреэклампсияангиогенные факторы ростаBrown M. et al. The classifi cation and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertension in pregnancy: offi cial journal of the International Society for the Study of Hypertension in Pregnancy. 2001: IX-XIV.Steegers E.A.P. et al. Pre-eclampsia. Lancet. 2010; 376 (9741): 631-44.Young B.C., Levine R.J., Karumanchi S.A. Pathogenesis of preeclampsia. Ann. Rev. Pathol. 2010; 5: 173-92.Granger J.P. et al. Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemia. Methods Mol. Med. 2006; 122: 383-92.Makris A. et al. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int. 2007; 71 (10): 977-84.Chaiworapongsa T. et al. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat. Rev. Nephrol. 2014; 10 (8): 466-80.Naljayan M. V., Karumanchi S.A. New Developments in the Pathogenesis of Preeclampsia. Adv. Chronic Kidney Dis. 2013; 20 (3): 265-270.Levine R.J. et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med. 2006; 355 (10): 992-1005.Conti E. et al. Growth factors in preeclampsia: A vascular disease model: A failed vasodilation and angiogenic challenge from pregnancy onwards? Cytokine Growth Factor Rev. 2013; 24 (5): 411-25.Verlohren S., Stepan H., Dechend R. Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia. Clin. Sci. 2011; 122(2): 43-52.Lassus P. et al. Vascular endothelial growth factor and angiogenin levels during fetal development and in maternal diabetes. Biol. Neonate. 2003; 84 (4): 287-92.Kleinrouweler C.E. et al. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: A systematic review and meta-analysis. BJOG An Int. J. Obstetr. Gynaecol. 2012; 119 (7): 778-87.Espinoza J. et al. Identifi cation of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am. J. Obstet. Gynecol. 2007; 196 (4): 326.e1-326.13.Levine R.J. et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 2004; 350 (7): 672-83.Maynard S.E. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 2003; 111 (5): 649-58.Shibuya M. Vascular endothelial growth factor and its receptor system: Physiological functions in angiogenesis and pathological roles in various diseases. J. Biochem. 2013; 153 (1): 13-9.Romero R. et al. An imbalance between angiogenic and anti-angiogenic factors precedes fetal death in a subset of patients: results of a longitudinal study. J. Matern. Fetal. Neonatal Med. 2010; 23 (12): 1384-99.Akolekar R. et al. Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia. Prenat. Diagn. 2010; 30 (3): 191-7.Foidart J.M. et al. Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia-a step forward but not the defi nitive answer. J. Reprod. Immunol. 2009; 82 (2): 105-10.Kusanovic J. P., Romero R., Chaiworapongsa T., Erez O. et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identifi cation of patients destined to develop preeclampsia. J. Matern. Fetal Neonatal Med. 2009; 22: 1021-38.Munaut C. et al. Differential expression of Vegfr-2 and its soluble form in preeclampsia. PLoS One. 2012; 7 (3): e33475.Powe C.E., Levine R.J., Karumanchi S.A. Preeclampsia, a disease of the maternal endothelium: The role of antiangiogenic factors and implications for later cardiovascular disease. Circulation. 2011; 123(24): 2856-69.Wada Y. et al. Effects of KRN633, an inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase, on vascular development of placenta and fetus of mid-pregnancy in mice. J. Pharmacol. Sci. 2010; 112 (3): 290-8.Levine R.J. et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med. 2006; 355 (10): 992-1005.Venkatesha S. et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 2006; 12 (6): 642-9.Mutter W.P., Karumanchi S.A. Molecular mechanisms of preeclampsia. Microvasc. Res. 2008; 75 (1): 1-8.Perni U. et al. Angiogenic factors in superimposed preeclampsia: A longitudinal study of women with chronic hypertension during pregnancy. Hypertension. 2012; 59 (3): 740-6.Lai J. et al. Maternal serum soluble endoglin at 30-33 weeks in the prediction of preeclampsia. Fetal Diagn. Ther. 2013; 33 (3): 149-55.Gaber K., Hamdy E., Hanafy A. Soluble Endoglin as a new marker for prediction of pre-eclampsia in early pregnancy. Middle East Fertil. Soc. J. 2010; 15 (1): 42-6.Hermes W., Kesteren F. Van, De Groot C.J.M. Preeclampsia and cardiovascular risk. Minerva Ginecol. 2012; 64 (4): 281-92.Chen C.W., Jaffe I.Z., Karumanchi S.A. Pre-eclampsia and cardiovascular disease. Cardiovasc. Res. 2014; 101 (4): 579-86.Jayet P.Y. et al. Pulmonary and systemic vascular dysfunction in young offspring of mothers with preeclampsia. Circulation. 2010; 122 (5): 488-94.Eremina V., Jefferson J.A., Kowalewska J., Hochster H. et al. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 2008; 358 (11): 1129-36.Spaan J.J. et al. Renal function after preeclampsia: A longitudinal pilot study. Nephron-Clin. Pract. 2012; 120 (3): 156-61.McDonald S.D. et al. Kidney Disease After Preeclampsia: A Systematic Review and Meta-analysis. Am. J. Kidney Dis. 2010; 55 (6): 1026-39.